ARTICLE | Clinical News
Dalvance dalbavancin regulatory update
April 7, 2014 7:00 AM UTC
FDA's Anti-Infective Drugs Advisory Committee voted 12-0 in favor of approval of Dalvance dalbavancin from Durata to treat acute bacterial skin and skin structure infections (ABSSSI). Durata is seekin...